Scholarlink

<p>Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. As a result of the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages. In recent years, locoregional and systemic therapies have increasingly been directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody–drug conjugates, have also improved outcomes in some patient subgroups. This clinical practice guideline for early-stage breast cancer (updated in 2025) is based on a systematic review of relevant studies and on the consensus of experts from the Spanish Breast Cancer Research Group (GEICAM), Spanish Collaborative Group for the Study, Treatment and Other Experimental Strategies in Solid Tumors (SOLTI), and Spanish Society of Medical Oncology (SEOM).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月29日

查看全文
  • Francisco Ayala de la Peña,
  • Silvia Antolín Novoa,
  • Joaquín Gavilá Gregori,
  • Lucía González Cortijo,
  • Fernando Henao Carrasco,
  • María Teresa Martínez Martínez,
  • Cristina Morales Estévez,
  • Agostina Stradella,
  • María Jesús Vidal Losada,
  • Eva Ciruelos

摘要

Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. As a result of the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages. In recent years, locoregional and systemic therapies have increasingly been directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody–drug conjugates, have also improved outcomes in some patient subgroups. This clinical practice guideline for early-stage breast cancer (updated in 2025) is based on a systematic review of relevant studies and on the consensus of experts from the Spanish Breast Cancer Research Group (GEICAM), Spanish Collaborative Group for the Study, Treatment and Other Experimental Strategies in Solid Tumors (SOLTI), and Spanish Society of Medical Oncology (SEOM).